Lessons from Eprex for biogeneric firms

Nat Biotechnol. 2003 Sep;21(9):956-7. doi: 10.1038/nbt0903-956.
No abstract available

Publication types

  • News

MeSH terms

  • Biotechnology / standards*
  • Drug Approval / legislation & jurisprudence*
  • Drug Industry / legislation & jurisprudence*
  • Drug Industry / standards*
  • Drug Industry / trends
  • Drugs, Generic / economics
  • Drugs, Generic / standards*
  • Erythropoietin / standards*
  • European Union
  • Product Surveillance, Postmarketing / standards*
  • Product Surveillance, Postmarketing / trends
  • Recombinant Proteins

Substances

  • Drugs, Generic
  • Recombinant Proteins
  • Erythropoietin